Sage Therapeutics (SAGE) to Release Earnings on Tuesday

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) is expected to be releasing its Q4 2024 earnings data after the market closes on Tuesday, February 11th. Analysts expect Sage Therapeutics to post earnings of ($1.54) per share and revenue of $14.37 million for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sage Therapeutics Trading Down 0.4 %

SAGE stock traded down $0.03 during midday trading on Wednesday, reaching $7.16. The stock had a trading volume of 1,789,664 shares, compared to its average volume of 2,488,442. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $27.39. The company's fifty day simple moving average is $6.34 and its 200 day simple moving average is $6.93. The company has a market cap of $437.98 million, a price-to-earnings ratio of -1.28 and a beta of 0.94.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SAGE. Royal Bank of Canada raised shares of Sage Therapeutics from an "underperform" rating to a "sector perform" rating and set a $4.00 target price on the stock in a research note on Thursday, November 21st. Oppenheimer cut their target price on Sage Therapeutics from $9.00 to $8.00 and set a "market perform" rating for the company in a research note on Wednesday, October 30th. Canaccord Genuity Group dropped their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a report on Wednesday. StockNews.com downgraded shares of Sage Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, October 31st. Finally, Wedbush reissued a "neutral" rating and issued a $6.00 price target on shares of Sage Therapeutics in a research note on Wednesday. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $9.65.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.